Physicians' Academy for Cardiovascular Education

Anti-inflammatory changes in response to PCSK9 antibody treatment in monocytes of FH patients

PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia

Literature - Bernelot Moens SJ, Neele AE, Kroon J et al., - Eur Heart J (2017) 00, 1–10. doi:10.1093/eurheartj/ehx002

Main results

Conclusion

Monocytes from FH patients not on statin therapy due to SAMS, show pro-inflammatory and migratory changes and an increase in cytoplasmic lipid droplets. The observations suggest a direct relation between intracellular lipid accumulation and inflammatory changes in monocytes. After 24-week treatment with a PCSK9 mAb anti-inflammatory changes were seen in monocyte migratory capacity, lipid content, and inflammatory responsiveness, towards a profile seen in FH patients on stable statin use. These changes were seen in the absence of a decrease in CRP levels.

References

Show references

Find this article at Eur Heart J

Share this page with your colleagues and friends: